Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1974 1
1979 1
1980 1
1983 1
1984 2
1985 2
1986 2
1987 3
1989 3
1990 6
1991 1
1992 3
1993 8
1994 8
1995 10
1996 11
1997 7
1998 5
1999 7
2000 8
2001 15
2002 31
2003 27
2004 32
2005 30
2006 48
2007 46
2008 73
2009 74
2010 67
2011 79
2012 77
2013 86
2014 83
2015 90
2016 127
2017 109
2018 109
2019 77
2020 68
2021 54
2022 50
2023 33
2024 2

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 15146409

1,323 results

Results by year

Filters applied: . Clear all
Page 1
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Keystone EC, et al. Arthritis Rheum. 2004 May;50(5):1400-11. doi: 10.1002/art.20217. Arthritis Rheum. 2004. PMID: 15146409 Free article. Clinical Trial.
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. Breedveld FC, et al. Arthritis Rheum. 2006 Jan;54(1):26-37. doi: 10.1002/art.21519. Arthritis Rheum. 2006. PMID: 16385520 Free article. Clinical Trial.
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. Weisman MH, et al. Clin Ther. 2003 Jun;25(6):1700-21. doi: 10.1016/s0149-2918(03)80164-9. Clin Ther. 2003. PMID: 12860493 Clinical Trial.
Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
Bingham CO 3rd, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME; GO-FURTHER Investigators. Bingham CO 3rd, et al. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1627-36. doi: 10.1002/acr.22556. Arthritis Care Res (Hoboken). 2015. PMID: 25623393 Free PMC article. Clinical Trial.
Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Emery P, Fleischmann RM, Doyle MK, Strusberg I, Durez P, Nash P, Amante E, Churchill M, Park W, Pons-Estel B, Xu W, Xu S, Wu Z, Hsia EC. Emery P, et al. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1732-42. doi: 10.1002/acr.22072. Arthritis Care Res (Hoboken). 2013. PMID: 23861303 Free article. Clinical Trial.
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE; ATTRACT Study Group. Smolen JS, et al. Arthritis Rheum. 2005 Apr;52(4):1020-30. doi: 10.1002/art.20982. Arthritis Rheum. 2005. PMID: 15818697 Free article. Clinical Trial.
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Maini RN, et al. Arthritis Rheum. 2004 Apr;50(4):1051-65. doi: 10.1002/art.20159. Arthritis Rheum. 2004. PMID: 15077287 Free article. Clinical Trial.
1,323 results